At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HRMY Harmony Biosciences Holdings, Inc.
Market Closed 02-20 16:00:00 EST
29.16
-5.23
-15.21%
盘后30.28
+1.12+3.84%
19:59 EST
High34.00Low28.00Vol5.45M
Open33.89D1 Closing34.39Amplitude17.45%
Mkt Cap1.68BTradable Cap1.30BTotal Shares57.60M
T/O160.86MT/O Rate12.23%Tradable Shares44.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: Harmony Biosciences Holdings, Inc. this quarter’s revenue is expected to increase by 19.55%, and institutional views are predominantly bullish
Earnings Agent  ·  02-17
Earning Preview: Harmony Biosciences Holdings, Inc. this quarter’s revenue is expected to increase by 19.55%, and institutional views are predominantly bullish
Harmony Biosciences downgraded to Hold from Buy at Truist
TIPRANKS  ·  02-21 05:05
Harmony Biosciences downgraded to Hold from Buy at Truist
Harmony Says FDA Approves Wakix for Cataplexy in Children With Narcolepsy
MT Newswires Live  ·  02-17
Harmony Says FDA Approves Wakix for Cataplexy in Children With Narcolepsy
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for Wakix® (Pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
THOMSON REUTERS  ·  02-17
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for Wakix® (Pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
Harmony Biosciences Cut to Neutral From Buy by UBS
Dow Jones  ·  02-11
Harmony Biosciences Cut to Neutral From Buy by UBS
Harmony Biosciences Holdings Inc. to Report Fourth Quarter and Full Year 2025 Financial Results
Reuters  ·  02-10
Harmony Biosciences Holdings Inc. to Report Fourth Quarter and Full Year 2025 Financial Results
Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares
Reuters  ·  01-29
Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares
Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares
Reuters  ·  01-21
Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares
Harmony Biosciences : Needham Raises Target Price to $46 From $42
THOMSON REUTERS  ·  01-20
Harmony Biosciences : Needham Raises Target Price to $46 From $42
Harmony Biosciences Holdings (HRMY) Receives a Buy from H.C. Wainwright
TIPRANKS  ·  01-13
Harmony Biosciences Holdings (HRMY) Receives a Buy from H.C. Wainwright
BRIEF-Harmony Biosciences Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation
Reuters  ·  01-12
BRIEF-Harmony Biosciences Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation
Harmony Biosciences Q4 Prelim Unaudited Net Product Revenue $243 Mln
THOMSON REUTERS  ·  01-12
Harmony Biosciences Q4 Prelim Unaudited Net Product Revenue $243 Mln
Harmony Biosciences: Wakix Net Revenue Projected Between $1.0 Bln - $1.04 Bln for 2026
THOMSON REUTERS  ·  01-12
Harmony Biosciences: Wakix Net Revenue Projected Between $1.0 Bln - $1.04 Bln for 2026
Harmony Biosciences Projects WAKIX Revenue to Surpass $1 Billion in 2026
Reuters  ·  01-12
Harmony Biosciences Projects WAKIX Revenue to Surpass $1 Billion in 2026
Harmony Biosciences Is Maintained at Buy by Truist Securities
Dow Jones  ·  01-09
Harmony Biosciences Is Maintained at Buy by Truist Securities
Harmony Biosciences price target lowered to $45 from $48 at Truist
TIPRANKS  ·  01-08
Harmony Biosciences price target lowered to $45 from $48 at Truist
Harmony Biosciences to Present at J.P. Morgan Healthcare Conference
Reuters  ·  01-07
Harmony Biosciences to Present at J.P. Morgan Healthcare Conference
Jeffrey M. Dayno, President and CEO, Reports Disposal of Harmony Biosciences Holdings Inc. Common Shares
Reuters  ·  2025-12-18
Jeffrey M. Dayno, President and CEO, Reports Disposal of Harmony Biosciences Holdings Inc. Common Shares
BRIEF-Beacon Biosignals Announces Partnership With Harmony Biosciences
Reuters  ·  2025-12-16
BRIEF-Beacon Biosignals Announces Partnership With Harmony Biosciences
Harmony Biosciences Partners with Beacon Biosignals to Advance EEG-Based Sleep Disorder Trials
Reuters  ·  2025-12-16
Harmony Biosciences Partners with Beacon Biosignals to Advance EEG-Based Sleep Disorder Trials

Introduction

Company Name.
Harmony Biosciences Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Issue price:
--